OAM
ACAD icon

OP Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

OP Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,098
Closed -$247K – 765
2026
Q1 		$247K Sell
11,098
-10,602
-49% -$253K ﹤0.01% 719
2025
Q4 		$580K Buy
21,700
+15,278
+238% +$365K 0.01% 640
2025
Q3 		$137K Sell
6,422
-32,718
-84% -$774K ﹤0.01% 749
2025
Q2 		$844K Buy
+39,140
New +$728K 0.01% 614

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OP Asset Management's ACAD Position: Q2 2026 in Review

OP Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 11,098 shares — an estimated $247K sold.

OP Asset Management first reported a position in ACAD in Q2 2025 and held it in 4 quarters. The position peaked at $844K in Q2 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • OP Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • OP Asset Management sold 11,098 Acadia Pharmaceuticals shares in Q2 2026, an estimated $247K.
  • OP Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • OP Asset Management's Acadia Pharmaceuticals position peaked at $844K in Q2 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on OP Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.